Dr. Chachoua Describes Clinical Trials Evaluating Immunotherapy in Lung Cancer

Abraham Chachoua, MD
Published: Wednesday, Jul 02, 2014

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

Chachoua says one clinical trial at NYU is examining chemotherapy versus immunotherapy in patients with non-small cell lung cancer (NSCLC) who have never been treated before. This will help researchers determine if immunotherapy upfront is better than chemotherapy, which is currently the standard treatment.

A third-line trial is also being conducted, Chachoua says, to examine an anti-PD compound that is being made by MedImmune.

NYU is opening a trial of ipilimumab, which is currently approved for the treatment of melanoma, in patients with lung cancer. This trial will analyze radiotherapy in conjunction with ipilimumab for patients with metastatic lung cancer. The trial will determine if using the combination of the antibody with radiation will enhance the immune response to the cancer. Chachoua says the trial is based on a patient experience at the Perlmutter Cancer Center.

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

Chachoua says one clinical trial at NYU is examining chemotherapy versus immunotherapy in patients with non-small cell lung cancer (NSCLC) who have never been treated before. This will help researchers determine if immunotherapy upfront is better than chemotherapy, which is currently the standard treatment.

A third-line trial is also being conducted, Chachoua says, to examine an anti-PD compound that is being made by MedImmune.

NYU is opening a trial of ipilimumab, which is currently approved for the treatment of melanoma, in patients with lung cancer. This trial will analyze radiotherapy in conjunction with ipilimumab for patients with metastatic lung cancer. The trial will determine if using the combination of the antibody with radiation will enhance the immune response to the cancer. Chachoua says the trial is based on a patient experience at the Perlmutter Cancer Center.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x